Yes-Associated Protein Expression in Head and Neck Squamous Cell Carcinoma Nodal Metastasis by Ge, Lin et al.
Yes-Associated Protein Expression in Head and Neck
Squamous Cell Carcinoma Nodal Metastasis
Lin Ge
2, Matthew Smail
1, Wenxia Meng
2, Yu Shyr
3, Fei Ye
3, Kang-Hsien Fan
3, Xiaohong Li
4, Hong-Mei
Zhou
5*, Neil A. Bhowmick
1*
1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, 2State Key Laboratory of Oral Diseases, Sichuan University,
Chengdu, Sichuan, China, 3Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, United States of America, 4Department of Cancer Biology, Vanderbilt
University, Nashville, Tennessee, United States of America, 5Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan,
China
Abstract
Introduction: Yes-associated protein (YAP) is considered an oncogene found amplified in multiple tumors, including head
and neck squamous cell carcinoma (HNSCC). However, the role for YAP expression in HNSCC is not understood. Based on
the central role of YAP in the hippo pathway, we tested if YAP was associated with the stage of HNSCC progression and
metastatic potential.
Methods: To determine the expression of YAP in human benign and HNSCC tissue specimens, immunohistochemical
analyses were performed in whole tissue samples and tissue microarrays. The expression of YAP in tissues of microarray was
first associated with clinic-pathologic factors and results verified in samples from whole tissue sections. To investigate the
role of YAP and p63 in regulating HNSCC epithelial to mesenchymal transition, epithelial and mesenchymal markers were
assayed in Fadu and SCC-25 cells, HNSCC cells with endogenously elevated YAP expression and siRNA-mediated expression
knockdown.
Results: Analysis of human HNSCC tissues suggested YAP expression was elevated in tumors compared to benign tissues
and specifically localized at the tumor invasive front (p value ,0.05). But, indexed YAP expression was lower with greater
tumor grade (p value =0.02). In contrast, p63 expression was primarily elevated in high-grade tumors. Interestingly, both
YAP and p63 was strongly expressed at the tumor invasive front and in metastatic HNSCC. Strikingly, we demonstrated YAP
expression in the primary HNSCC tumor was associated with nodal metastasis in univariate analysis (p value =0.02).
However, the knockdown of YAP in Fadu and SCC-25 cell lines was not associated with changes in epithelial to
mesenchymal transdifferentiation or p63 expression.
Conclusion: Together, YAP expression, in combination with p63 can facilitate identification of HNSCC tumors from
hyperplastic and benign tissues and the metastatic function of YAP in HNSCC may not be a result of epithelia to
mesenchymal transdifferentiation.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) can involve
oral cavity, larynx and laryngeal pharynx. Oral squamous cell
carcinoma (OSCC) represents 90% of oral cancers. Alterations in
the 11q22 amplicon is detected in 5–15% of OSCC [1]. The gene,
Yes-associated protein (YAP), located in 11q22, is specifically
amplified in 4/23 of OSCC [2]. YAP was initially proposed as an
oncogene following the identification of its expression in mouse
tumor models [3,4]. Later, multiple groups reported the up regula-
tion of YAP in human cancers including those in the prostate,
ovary, and colon [5,6]. YAP is a critical transcription factor in the
Hippo signaling pathway, initially identified for sensing and
regulating organ size [7]. As such, YAP disregulation was further
proposed as candidate oncogene in hepatocellular carcinoma,
non-small-cell lung carcinoma, esophageal squamous cell carcino-
ma, ovarian cancer, gastric cancer [7–11]. However, in breast
cancer, YAP is considered a tumor suppressor, based on reduced
xenografted mammary tumor size in the context of YAP
knockdown [8]. Opposing functions in different anatomical tissues
might be due to its role with p53 family of proteins including p73
and p63, as well as interactions with transcription enhancer factor
(TEF/TEAD) [12–17]. YAP is reported to cause EMT, stimulate
proliferation, inhibit apoptosis, and promote tumor progression in
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27529a tissue-specific manner [7,9]. The specific role of YAP in HNSCC
is examined in this study.
A hallmark of HNSCC progression is elevated expression of the
protein p63. P63 has two mRNA products from independent
promoters, with each mRNA having three splice variants giving
altered C-termini. Of the six p63 isoforms, delta-Np63 alpha is
dominant in high grade HNSCC [10,11]. Recently YAP was
reported to promote the degradation of delta-Np63 alpha in head
and neck carcinoma cell lines [12]. Further, Np63 binds the YAP
promoter and repress its expression [21]. Thus, an inverse
correlation between Np63 and YAP was speculated in patient
tissues. However, the inverse relationship between YAP and p63
expression was not supported in human HNSCC tissues or cell
lines. Our data indicated that elevated YAP expression differen-
tiates hyperplastic and low grade HNSCC from benign head and
neck tissues, with an unexpected decrease in expression in high
grade HSCC. However, there was consistent elevation of YAP
expression localized at the HNSCC tumor invasive edge.
Interestingly, YAP expression or its knockdown did not affect
epithelial-mesenchymal transition (EMT) progression in HSCC
cell lines, nor did it affect p63 expression. The role of YAP
expression in differentiating benign head and neck tissue from
HNSCC can support its use as a marker to complement p63 in
identifying tumor margins.
Methods
Ethics Statement
The study was performed with the written approval of the
Ethics Committee of West China College of Stomatology, Sichuan
University. We acquired written consent from all patients. The use
of the data from the tissues was considered exempt by the
Institutional Review Board at Vanderbilt University.
Patients and samples
Twenty-three OSCC patients and six oral leukoplakia patients
confirmed by pathologic diagnosis were ` included in this study.
Among them, 22 primary tumor samples of OSCC had been
obtained from 2004 to 2008, with a 34-month median follow-up
period (25–73 month range). Six patients undergoing orthodontic
surgery were involved as benign controls. Tissue samples from
total thirty-five patients were collected during surgery or biopsy
after obtaining informed consents from patients in West China
Hospital of Stomatology. Samples were fixed in 10% neutralized
formalin and then embedded in paraffin. Additionally, a tissue
microarray (TMA) (‘‘Oral squamous cancer tissue array with
normal oral control tissue’’ from Imgenex, San Diego, CA, USA
and ‘‘Multiple head and neck tumor with normal tissue array, with
stage and grade info, 80 cases/80 cores ‘‘ from Biomax, Rockville,
MD, USA) contained 128 tissue cores of benign, benign adjacent
to tumor and squamous cell carcinoma tissues. With the exception
of the benign samples, the clinical and pathological information of
the malignant samples is arranged in Table 1.
Antibodies and immunohistochemistry
Paraffin-embedded tissue sections (5 mm) were deparaffinized
and hydrated through xylene and graded alcohols using a standard
protocol [13–15]. A volume of 1% antigen unmasking solution
(Vector laboratories, Burlington, CA, USA) or Tris-EDTA buffer
(10 mM Tris Base, 1 mM EDTA solution, pH 9.0) was used for
antigen retrieval depending on the antibodies. Subsequent
immunohistochemical staining used antibodies against YAP
(1:200, Santa Cruz Biotech, Santa Cruz, CA, USA) vimentin E-
cadherin and p63 4A4 (1:1000, Santa Cruz). Appropriate HRP-
conjugated secondary antibodies and DAB incubation (Dako
North America, Carpinteria, CA, USA) were used for visualiza-
tion. The intensity of YAP staining was classified as negative
(score 0), weak positive (score 1), positive (score 2), strong positive
(score 3). The percentage of positive cells in total malignant
cells was counted. Three (for TMA) or five (for paraffin blocks)
independent fields were acquired for each section. The final
index was obtained by multiplying the intensity with the
percentage. The calculation of index for cytoplasmic and nuclear
staining was performed independently. Since rare nuclear staining
appears in TMA, oral benign lesions and normal tissues in paraffin
blocks, the indexed YAP expression only stands for cytoplasmic
Table 1. The source, clinical and pathological information of malignant samples.
OSCC patients (22) Imgenex (44) Biomax (58)
Organ Dermal 1 3 3
upper aerodigestive 1 0 44
Oral cavity 19 41 7
Bone 1 0 4
Sex Female 6 17 10
Male 16 27 48
Grade Poorly to moderately 8 36 35
well 14 8 23
Stage III–IV 12 N/A 38
I–II 10 N/A 20
Nodal metastasis Yes 4 N/A 18
No 18 N/A 40
Recurrence or metastasis Yes 5 N/A N/A
No 12 N/A N/A
missing 5 N/A N/A
doi:10.1371/journal.pone.0027529.t001
YAP in Head and Neck Squamous Cell Carcinoma
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positive cells.
Cell culture, transfection and Western blot analysis
The Fadu cell line was kindly gifted by Dr. Yarbrough
(Vanderbilt University). It was cultured in high glucose Dulbecco’s
Modified Eagle’s Medium, supplemented with 10% fetal bovine
serum and 0.1% penicillin/streptomycin. Fadu cells were
transfected with YAP or scrambled siRNA (Santa Cruz Biotech).
The cells were harvested 48 h following transfection and analyzed
by Western blotting for YAP, p63, vimentin, E-cadherin or beta-
actin (Santa Cruz). Respective horseradish peroxidase conjugated
secondary antibodies (GE Healthcare, Piscataway, NJ, USA) were
used to visualize the expression of proteins.
Statistical analysis
YAP protein expression levels of the HNSCC tumor tissues
were measured by cytoplasmic staining using the technique
involved tissue microarray. Three data sets were first pooled
together and a categorical variable called "type" was created
(Table 1). "Type" refers to the data set that the observation comes
from. It has three levels, "Imgenex", "Biomax" and "OSCC". For
each variable, a linear model that includes this variable, type and
variable-by-type interaction was fitted. If the interaction was not
significant by analysis of variance (ANOVA), the interaction was
removed from the data and a new linear model that included the
variable and type was fitted again. YAP expression association
with tumor grade, stage, metastasis status, and other patient
variables were determined by univariate analysis. Of note, limited
clinical information was available on the status of differentiation,
stage, nodal metastasis. Np63 expression was correlated with
indexed YAP staining using Pearson analysis. Descriptive statistics,
including means, standard deviations, and ranges for continuous
variables, as well as percent and frequencies for categorical
variables, are presented in Table 2. In general, hypotheses were
tested at the level of a=0.05. Point estimates along with the
corresponding p-values and 95% confidence intervals are reported
(Table 2). Statistical analysis was carried out using R (Version
2.10.1).
Results
YAP expression levels correlate with head and neck
squamous cell carcinoma and pathologic grade
YAP expression in the tissue arrays of HNSCC and benign
samples were analyzed by immunohistochemistry. HNSCC had
high YAP expression compared to oral benign tissue or benign
tissue adjacent to tumor. YAP expression was further localized in
cancer and specifically elevated at the tumor borders (Figure 1).
Additionally oral leukoplakia tissues from paraffin blocks had
similar expression to oral benign tissues, where epithelium of the
suprabasal layer had both cytoplasmic and nuclear YAP
localization. The basal and parabasal cells of oral leukoplakia
had primarily cytoplasmic YAP expression. The TMA of
independent patients illustrated dramatic differences between
malignant and benign tissues, where YAP staining of benign
tissues in TMA were near undetectable. The quantitative data of
indexed YAP expression illustrated in Figure 2 are derived from
paraffin sections of whole tissues, as these can be best assessed
pathologically for tumor margins (n=35, p value #0.05). Careful
analysis of whole tumor tissue sections revealed that the stromal
compartment containing fibroblasts and endothelial cells in the
benign tissues did not express YAP. However, the stromal
compartment adjacent to carcinoma tissue generally had up-
regulated YAP expression. The tissue and cellular distribution
pattern of YAP expression interestingly associated with cancer
status of the epithelia.
The expression of YAP was next correlated to clinical
information of tumor progression. Univariate analysis indicated
a significant difference in YAP expression with respect to the
variables of differentiation and nodal metastasis, as opposed to
tumor grade (Table 2). So, the result from a larger sample set
demonstrated that YAP cytoplasmic expression increased in well-
differentiated squamous cell carcinoma compared with poorly
differentiated (p value =0.02). However, the data from 80
patients, suggested that nodal metastasis was associated with up
regulation of YAP cytoplasmic expression (p value =0.02). Other
covariates such as age, sex, organ site, and stage did not have
differences in YAP expression (Table 2). Based on known
expression of delta-Np63 alpha in high grade HNSCC [10,11]
Table 2. Regression analysis for YAP cytoplasmic staining.
variables Observations univariate
Coefficient estimate (95% confidence interval) p-value
Age 124
.60 y vs. #60 y 0.12 (2.29,.52) 0.85
Sex 124
female vs. male 12.84 (218.42,44.10) 0.42
Grade 124
poorly vs. well differentiated 234.81 (263.934, 25.685) 0.02
Stage 80
III–IV vs. I–II 10.31 (222.51,43.13) 0.53
Nodal metastasis 80
yes vs. no 41.66 (7.15,76.17) 0.02
Recurrence or Metastasis 22
yes vs. no 37.18 (225.041, 99.407) 0.23
missing vs. no 3.98 (258.241,66.207) 0.9
doi:10.1371/journal.pone.0027529.t002
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Np63 alpha [12], we tested the presence of an in vivo correlation
of YAP expression and delta-Np63 alpha in serial sections from
paraffin blocks. We observed the intensity of YAP decreases with
elevated p63 expression and higher grade (Figures 3 and 4).
The expression of YAP and invasive progression of head
and neck squamous cell carcinoma
Most strikingly, we observed differences in YAP expression
within the tumor, where the margins of frank tumor had strong
YAP expression compared to proximal areas (Figure 5). Interest-
ingly, HNSCC areas of invasion had both strong YAP and p63
expression compared to the body of the tumor. While, p63 was
localized exclusively in the nucleus, YAP epithelial expression was
observed in both nuclear and cytoplasmic compartments. This
observation was consistent with the observation in cell culture
where YAP expression was elevated in cells on the edge or cells in
small clusters [6]. But, the parallel correlation of p63 and YAP
expression has not been made previously.
The relevance of elevated YAP expression at the tumor margins
was rationalized to be potentially associated with EMT, as it has
been in the past. Further correlation of YAP to p63 expression was
tested in two established HNSCC cell lines. To determine if YAP
was associated with EMT progression in head and neck cancer,
Western blots for Fadu and SCC-25 human HNSCC cells were
performed. We found that both had endogenously elevated YAP
expression, with Fadu cells having significantly greater expression
compared to the SCC-25 (Figure 5). P63 was expressed similarly in
both lines. Interestingly, Fadu and SCC-25 cells expressed both
the epithelial marker, E-cadherin, and mesenchymal marker,
vimentin. To determine the impact of YAP expression on p63 and
EMT markers, we knocked down YAP expression by siRNA.
Western blotting and used immunofluorescence to localize the
expression of the proteins in the context of YAP knockdown
(Figures 5, 6, 7). However, the knockdown of YAP did not change
p63 expression. Despite previous reports of the role of YAP in
EMT, there were little changes in expression of EMT associated
proteins, E-cadherin or vimentin, in independent Western blot
Figure 1. YAP protein expression was localized by immunohistochemistry in head and neck squamous cell carcinoma (HNSCC). (A)
Tissue microarray data suggested YAP was up-regulated in HNSCC compared with benign tissue and benign tissue adjacent to tumor. (B) YAP was
weakly expressed in the cytoplasm of basal cells, parabasal cells and suprabasal cells. Occasional expression of YAP in the nucleus of suprabasal cells
in oral benign tissue and oral leukoplakia tissue was detected. (C) YAP expression was localized in the nucleus of stromal fibroblasts and (D) the
cytoplasm of endothelial cells, as well as both cytoplasm and nucleus of HNSCC epithelia.
doi:10.1371/journal.pone.0027529.g001
Figure 2 Indexed YAP expression in benign and HNSCC. (A) Malignant tissues presented a significantly greater indexed YAP staining
compared to benign tissues (N=35, P,0.05). (B) YAP expression, indexed by staining intensity, was correlated to HNSCC grades 1–3 (N=80). The
elevated YAP expression in Grade 1 HNSCC was significantly greater than that found in grades 2 and 3. There was no statistical difference between
the expression of YAP in grades 2 and 3.
doi:10.1371/journal.pone.0027529.g002
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immune-localization of p63, E-cadherin, and vimentin expression
in Fadu and SCC-52 cells in control and YAP knocked down
conditions. The added co-staining for F-actin enabled visualization
of the maintenance of cortical actin structures in the both control
and YAP knockdown conditions (Figure 7). Thus, the clear
differential expression of YAP in metastatic and non-metastatic
HNSCC patient tissues and interesting expression at the tumor
margins was likely not a result of its role in EMT. Together, the
data supports an alternative role for YAP expression in HNSCC
and its association with greater nodal metastatic progression.
Discussion
The study was focused on YAP expression patterns in head and
neck squamous cell carcinoma and oral squamous cell carcinoma.
Indexed YAP expression correlated with HNSCC tissue grade,
site, and nodal metastasis through univariate analysis. Similarly,
the analysis of OSCC tissues indicated a significant association of
indexed YAP cytoplasmic expression with nodal metastasis. The
clinical indicators, organ, differentiation grade and nodal metas-
tasis were significantly correlated to the index of YAP staining.
The index of YAP expression was elevated in well-differentiated
HNSCC and diminished in higher grade HNSCC. This inverse
correlation of YAP and HNSCC differentiation status differed
from reports in liver cancer [16], but was similar to that found in
breast cancer [7]. It implied the possible correlations between YAP
cytoplasmic expression and these variables. But, regardless of
HNSCC tumor grade, YAP expression was markedly higher at the
tumor margins. Although we do not understand the apparent
correlation of tumor differentiation status and YAP expression
observed, the association with nodal metastasis implied the
migration ability of YAP, consistent with previous reports [17–
Figure 3. Correlation between YAP and p63 expression was identified in hyperplastic, grade 1, and grade 2 HNSCC. In hyperplastic
tissue, p63 was expressed in basal and para-basal cells, whereas YAP was localized primarily in basal compartment. In grade 1 HNSCC, the number of cells
expressing p63 was found in approximately 50% of the epithelial cell and YAP was strongly expressed in the basal layer with significant added expression
in the stromal compartment. For grade 2 HNSCC, p63 was expressed in nearly all the malignant epithelial cells with significant decrease YAP expression.
doi:10.1371/journal.pone.0027529.g003
Figure 4. YAP expression in the HNSCC tumor invasive front is
up regulated. (A) YAP expression was up regulated in the cytoplasm as
well as expressed in the nucleus at the tumor edge. The colored boxes
(yellow,orange,red)inthetoppanelsareexpandedinthecorresponding
panels below according to the respective colored lines on the left. This
was done to specifically illustrate the differences in YAP expression at the
distal tumor margins versus the proximal central region. (B) Malignant
cells directly within the invasive front specifically had high nuclear YAP
expression and high p63 expression. The scale bar represents 200 mm
and 25 mm in the primary and inset images, respectively.
doi:10.1371/journal.pone.0027529.g004
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contributed to the migration ability of tumor cells [22,23].
We sought to resolve this discrepancy in indexed YAP
expression with decreasing stage yet association with metastasis.
We observed YAP nuclear expression diminished with increasing
clinical stage. However, cytoplasmic YAP indexed expression
increased with incidence of HNCC nodal metastasis. A previous
report of cytoplasmic YAP localization suggested a proliferative
advantage in HNSCC [21]. The liver has elevated cytoplasmic
YAP expression in poorly-differentiated carcinoma [24]. However,
in benign tissues, YAP was more frequently expressed in the
suprabasal cells as well as basal cells compared to parabasal cells,
whose differentiation level lies between the former two types of
cells. The results implied no correlation between p63, a basal cell
marker, and YAP. However, we identified the inversed expression
patterns of YAP and p63 in some specific phenotypes: 1) P63 was
expressed in the parabasal cells of benign tissues in which YAP was
not expressed (Figure 1) [25]. 2) P63 expression in poorly-
differentiated HNSCC had little to no YAP expression (Figures 3
and 4). 3) Finally, YAP expression in benign suprabasal cells and
well-differentiated HNSCC had little expression of p63 (Figure 3).
The observed inverse expression of p63 and YAP was supported
by the report that YAP expression mediates p63 degradation [12].
Yet, at the tumor’s invasive front, p63 and YAP were both
expressed.
The specific localization of YAP in cells at the tumor margins
(Figure 4) and association with nodal metastasis initiated our
studies on its role in metastatic progression. Based on mechanisms
Figure 5. The YAP expression was not associated with p63 and
EMT marker regulation in Fadu and SCC-25 cells. Western blot of
(A) Fadu and (B) SCC-25 cells in control and those with YAP knocked by
siRNA, had similar expression levels of p63, vimentin and E-cadherin.
Beta-actin was used as a loading control.
doi:10.1371/journal.pone.0027529.g005
Figure 6. YAP expression does not affect E-cadherin and vimentin localization in the Fadu human HNSCC cell line.
Immunofluorescent localization of E-cadherein, and vimentin was performed in control and YAP siRNA knocked down Fadu cells.
doi:10.1371/journal.pone.0027529.g006
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collective cell movement, we tested if YAP expression correlated
with EMT or contact inhibition, respectively. Recently the ligand
of epidermal growth factor receptor, amphiregulin, was reported
to contribute to the proliferation and migration function of YAP in
MCF10A [26]. YAP over expression in MCF10A, a breast non-
transform cell line, can cause EMT [3,27]. Thus far, the role of
YAP in EMT has been carried out in MCF10A, which does not
endogenously express YAP. Thus, we used Fadu and SCC-25
cells, common HNSCC cell lines that expresses YAP. However,
traditional markers of EMT progression were not altered by YAP
knockdown. (Figures 6, 7). Interestingly, in cell culture, greater
YAP expression was found on the edges of cell clusters [6]. The
contact inhibition function was first described in organ size control
research. The over expression of YAP lead to liver size expansion,
resulted from unrestricted cell proliferation [28,29]. Thus, YAP
expression in HNSCC may function as a means of sensing tissue/
tumor size at the leading edge of tumor margins.
The expression of YAP in carcinoma tissues, compared to
benign or benign adjacent tissues was dramatic. Hyperplastic
tissues, such as papillomas, were found to have elevated YAP
expression. In further examination of YAP expression in
leukoplakia, a precancerous disease with a 10% chance to become
OSCC, we found it was similar to benign tissue (Figure 1). The
concept of field cancerization, was initially proposed in HNSCC,
to describe changes in epithelial cells adjacent to the cancer. Some
of these changes in the non-transformed cells were associated with
genetic alteration and could not be considered benign tissue. We
found YAP was over-expressed in malignant cells of HNSCC as
well as associated endothelia and fibroblasts. Similar YAP
expression was not observed in parallel benign and precancerous
tissues. On the whole expression levels of benign tissues or
hyperplastic tissues appeared lower compared to that of carcinoma
tissues. Thus, YAP expression can serve as a marker to distinguish
pre-malignant and malignant progression of HNSCC in tissue
sections that may have otherwise ambiguous tumor margins.
Currently, histologic cues and p63 expression help determine
margins of HNSCC. The additional use of YAP expression may
benefit the verification of histological low-grade HNSCC.
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